Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Investigated for use/treatment in strokes, cerebral ischemia, and depression.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.